Skip to content
DataLookout
Menu

Bladder Cancer clinical trials

Get alerts when Bladder Cancer trials change
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-22

What changed in the last 30 days

93 trials changed in the last 30 days: 3 stopped, 39 with notable changes, 51 with minor changes only.

  1. Notable: Trastuzumab Rezetecan · HER2-Expressiong Advanced Solid Tumor Recruitment opened Haihua YuanPhase 2 NCT07631884
  2. Notable: Zanidatamab in HER2-positive Advanced Tumor After at Least One Line of Standard Therapy Recruitment opened Haihua YuanPhase 2 NCT07631871
  3. Notable: IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors Enrollment increased: 260 → 570 participants IDEAYA BiosciencesPhase 1 NCT07277413
  4. Minor: AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, · Unresectable Locally Advanced or Metastatic Cancer Enrollment closed, study ongoing Aulos Bioscience, Inc.Phase 1/2 NCT05267626
  5. Minor: Bladder EpiCheck European Haematuria Study Enrollment closed, study ongoing Nucleix Ltd.Not specified NCT06818136
  6. Minor: Symbiotic-GU-06 · PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer Trial sites expanded: 184 → 198 locations PfizerPhase 1/2 NCT07421700
  7. Minor: 68Ga/177Lu-BRP-020063 in Advanced Solid Tumors Primary and study completion pushed from Aug 31, 2026 to Dec 31, 2026 Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineEarly Phase 1 NCT07439120
  8. Minor: Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) · Muscle Invasive Bladder Cancer (EV-309) Trial sites expanded: 29 → 37 locations Astellas Pharma Global Development, Inc.Phase 3 NCT07566156
  9. Notable: EHR Integrated Remote Patient Monitoring to Reduce Readmission · Bladder Cancer Undergoing Cystectomy Recruitment opened University of Michigan Rogel Cancer CenterNot applicable NCT07912034
  10. Notable: Nectin-4 Specific LMW PET Probe Imaging in Multiple Solid Tumors Enrollment increased: 20 → 40 participants Peking University Cancer Hospital & InstituteNot applicable NCT05321316
  11. Minor: Real-world Study to Learn About of the Characteristics and Outcomes of Advanced or Metastatic Bladder Cancer · Different Histologies Trial status changed: Not Yet Recruiting → Active, Not Recruiting PfizerNot specified NCT07897669
  12. Minor: Vanguard Study: Testing a New Way to Screen for Cancer Trial sites expanded: 44 → 49 locations National Cancer Institute (NCI)Not applicable NCT06995898
  13. Stopped: Tocilizumab, Ipilimumab, and Nivolumab · Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma Trial terminated M.D. Anderson Cancer CenterPhase 2 NCT04940299
  14. Notable: HER3-DXd · Locally Advanced or Metastatic Solid Tumors Primary completion pushed from Sep 1, 2027 to Nov 19, 2030 Daiichi SankyoPhase 2 NCT06172478
  15. Notable: Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial Results posted: Nov 17, 2026 National Cancer Institute (NCI)Phase 2 NCT04216290
  16. Notable: IAM1363 in HER2 Cancers Primary completion pushed from Dec 2027 to Oct 2028 Iambic Therapeutics, IncPhase 1/2 NCT06253871
  17. Notable: TRAIN · Control Clinical Trial of Radiotherapy With Radiosensitisation Versus Intravesical Bacillus Calmette-Guerin Therapy for High-risk Non-muscle Invasive Bladder Cancer Recruitment opened The Christie NHS Foundation TrustPhase 3 NCT07268339
  18. Minor: TroFuse-031 · Sacituzumab Tirumotecan (Sac-TMT, MK-2870) · Urothelial Cancer (MK-2870-031) Trial sites expanded: 111 → 117 locations Merck Sharp & Dohme LLCPhase 3 NCT07419295
  19. Minor: Erdafitinib (JNJ-42756493) · Urothelial Cancer Study completion pushed from Mar 31, 2027 to Dec 31, 2027 Janssen Research & Development, LLCPhase 2 NCT02365597
  20. Minor: LB-LR1109 · LB-LR1109, Administered Alone · Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC Study completion pushed from Mar 2028 to Dec 2028 LG ChemPhase 1 NCT06332755
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

New sponsor entrants, last 90 days sponsors with their first trial in this area

First postedTrialSponsorPhase
2026-11-20 NCT07951060 LP-184 for Advanced or Metastatic Urothelial Carcinoma Selected by PTGR1 Expression and… Kristoffer Rohrberg new Phase 1/2
2026-11-20 NCT07950826 Hybrid Versus Wallace and Bricker Ureteroenteric Anastomosis After Radical Cystectomy… Başakşehir Çam & Sakura City Hospital new
2026-11-13 NCT07936422 A Trial Evaluating the Anti-tumor Activity of Antibody-based Therapies in Metastatic… Centre Leon Berard new Phase 2
2026-11-10 NCT07927400 An Exploratory Study of the Efficacy and Safety of SBRT Following Induction Therapy With… Tianjin Medical University Cancer Institute and Hospital new
2026-11-09 NCT07924046 Diagnostic Performance of Multiparametric Magnetic Resonance Imaging After Transurethral… University of Lausanne Hospitals new
2026-10-27 NCT07898033 1 Year Recurrence After Modified en Bloc Resection (ERBT) vs Transurethral Resection… dmitry enikeev new Phase 3
2026-10-26 NCT07893509 Outcomes for IR and High Risk (HR) Non-muscle Invasive Bladder Cancer (NMIBC) and… Bladder Cancer Advocacy Network new
2026-10-19 NCT07881666 Inactivated UPEC-FimON for Non Muscle Invasive Bladder Cancer After BCG or Intravesical… Hopec Pharma new Phase 1
2026-10-06 NCT07860398 Feasibility of Automatic, Laser-based Distance Control in Persons With Superficial… Optheras AS new
2026-10-02 NCT07855926 Perioperative Systemic Therapies in Muscle-Invasive Bladder Cancer (GUARDIANS) LMU Klinikum new

Active trials by phase

Early Phase 1
14
Phase 1
110
Phase 1/2
87
Phase 2
217
Phase 2/3
15
Phase 3
86
Phase 4
11
Not charted: 355 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).
Get alerts when Bladder Cancer trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.
Start monitoring free

Narrower conditions

Active trials